Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and
current treatments are less than satisfactory. So, the discovery of novel approaches to treat …

Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic
neurotransmission may be modulated at multiple levels, only a minority of which are …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects
millions of individuals worldwide. To date, the monoaminergic systems (serotonin …

Depressive disorders are among the most common psychiatric conditions and contribute to
significant morbidity. Even though the use of antidepressants revolutionized the …

Tianeptine is a clinically used antidepressant that has drawn much attention, because this
compound challenges traditional monoaminergic hypotheses of depression. It is now …

Depression is a highly debilitating disorder that has been estimated to affect up to 21% of
the world population. Despite the advances in the treatment of depression with selective …

Anxiety and stress-related disorders, namely posttraumatic stress disorder (PTSD),
generalized anxiety disorder (GAD), obsessive–compulsive disorder (ODC), social and …

Depression and anxiety represent a major problem. However, the current treatment of both
groups of diseases is not satisfactory. As the glutamatergic system may play an important …

Medicinal therapies for mood disorders neither fully serve the efficacy needs of patients nor
are they free of side-effect issues. Although monoamine-based therapies are the primary …